J&J ($JNJ) drops Arena ($ARNA) diabetes drug pact

Johnson & Johnson ($JNJ) has decided to end its deal for Arena Pharmaceuticals' ($ARNA) diabetes drug APD597 after seeing Phase I results. APD597 is a GPR119 agonist for type 2 diabetes, which, along with other compounds and intellectual property, will revert to Arena upon termination of the collaboration. Arena release

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.